EDITION:
- EU
- NA
Oxford Cannabinoid Technologies Holdings, one of the UK’s few remaining pharmaceutical cannabis companies, appears to have entered administration.Â
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2 clinical trial for AJA001, a cannabinoid-based (FDA) botanical drug developed to treat behavioral symptoms associated with autism spectrum disorder (ASD).
THE central European nation of Slovenia is developing proposals which could establish a continental benchmark for medical cannabis. Governing coalition
In recent years, the pharmaceutical landscape has witnessed a seismic shift as cannabinoids transition from niche alternatives to mainstream medical solutions.
Kingdom Therapeutics, a UK-Irish biotech company, has passed a ‘major milestone’ in its ambitious journey towards launching clinical trials into cannabis and Autism Spectrum Disorder (ASD)
A biopharmaceutical company is suing the Drug Enforcement Administration (DEA) over what it called unjustified delays to its application to
Advancing Pharmaceutical Innovation: Brains Bioceutical’s CEP Certification will Streamline Cannabinoid Drug Development, Inspired by Jazz Pharmaceuticals’ CBD-Based Epilepsy Drug and
As reported by Cannabis Health Avata Biosciences is developing solid dose cannabinoid medicines for epilepsy and other neurological disorders, with
A NEW landmark study into the effects of cannabidiol (CBD) on psychosis is scheduled to be launched ‘later this year’.
CANADIAN CANNABIS PRICES Canadian wholesale cannabis prices are off more than 40% in 2022 Canadian cannabis wholesale prices tumbled more
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
